Abstract:Levofloxacin is a fluoroquinolone antibiotic and is the optical S-(−) isomer of the racemic drug substance ofloxacin. It has a broad spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, as well as certain other pathogens such as Mycoplasma, Chlamydia, Legionella and Mycobacteria spp. Levofloxacin is significantly more active against bacterial pathogens than R- (+) - ofloxacin. Levofloxacin hemihydrate, the commercially formulated product, is 97.6% levofloxacin by weight.Levofloxacin pharmacokinetics are described by a linear 2-compartment open model with first-order elimination. Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively. The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food. Oral absorption is very rapid and complete, with little difference in the serum concentration-time profiles following 500mg oral or intravenous (infused over 60 minutes) doses.Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg·h/L, respectively, both increasing linearly in a doseproportional fashion. The pharmacokinetics of levofloxacin are similar during multiple-dose regimens to those following single doses. Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids. Drug concentrations in tissues and fluids are generally greater than those observed in plasma, but penetration into the cerebrospinal fluid is relatively poor (concentrations approximately 16% of simultaneous plasma values). Levofloxacin is approximately 24 to 38% bound to serum plasma proteins (primarily albumin); serum protein binding is independent of serum drug concentrations.The plasma elimination half-life (t½β) ranges from 6 to 8 hours in individuals with normal renal function. Approximately 80% of levofloxacin is eliminated as unchanged drug in the urine through glomerular filtration and tubular secretion; minimal metabolism occurs with the formation of no metabolites possessing relevant pharmacological activity. Renal clearance and total body clearance are highly correlated with creatinine clearance (CLcr), and dosage adjustments are required in patients with significant renal dysfunction. Levofloxacin pharmacokinetics are not appreciably affected by age, gender or race when differences in renal function, and body mass and composition are taken into account.Important drug interactions exist with aluminium- and magnesium-containing antacids and ferrous sulfate, as with other fluoroquinolones, resulting in significantly decreased levofloxacin absorption when administered concurrently. These agents should be administered at least 2 hours before or after levofloxacin administration. Cimetidine and probenecid decrease levofloxacin renal clearance and increase t½β; the magnitudes of these interactions are not clinically significant. Levofloxacin appears to have only minor potential for significantly altering the pharmacokinetics of theophylline, warfarin, zidovudine, ranitidine, digoxin or cyclosporin; however, patients receiving these drugs concurrently should be monitored closely for signs of enhanced pharmacological effect or toxicity. Levofloxacin pharmacokinetics are not significantly altered by sucralfate when administration of these drugs is separated by at least 2 hours.

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetics And Pharmacodynamics Of Levofloxacin Injection In Healthy Chinese Volunteers And Dosing Regimen Optimization

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization

Phamacodynamics and pharmacokinetics of levofloxacin in patients with lower respiratory tract infection

Pharmacodynamics and Pharmacokinetics of Levofloxacin

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Observation on clinical effects of intravenous levofloxacin 500 mg once-daily vs 300 mg twice-daily in the treatment of lower respiratory tract bacterial infections

Population Pharmacokinetics of Oral Levofloxacin 500mg Once-Daily Dosage in Community-Acquired Lower Respiratory Tract Infections: Results of a Prospective Multicenter Study in China

The Clinical Pharmacokinetics of Levofloxacin

An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Efficacy and Safety of Oral Levofloxacin 500 Mg Once Daily in Patients with Lower Respiratory Tract Infections or Urinary Tract Infections

Pharmacokinetics of single 500-milligram doses of intravenous levofloxacin in middle-age healthy volunteers

Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

Pharmacokinetics of levofloxacin in patients with pneumonia

Levofloxacin for the treatment of respiratory tract infections

Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects.

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection

Levofloxacin: a therapeutic review

Levofloxacin: an updated review of its use in the treatment of bacterial infections

Pharmacokinetics of Levofloxacin Hydrochloride Soft Capsules, Hard Capsules and Tablets in Chinese Healthy Volunteers

Clinical evaluation of levofloxacin sequential therapy in the treatment of 214 patients with bacterial infections

A Review of Levofloxacin for the Treatment of Bacterial Infections